Items Tagged ‘Pancreatic Cancer’

July 11th, 2017

Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising

By

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking place June 28 through July 1, 2017 in Barcelona, Spain. AM0010 is being evaluated in an ongoing Phase 1/1b clinical trial that has enrolled 352 advanced cancer patients and in a […]

View full entry

Tags: AM0010, immunotherapy, Interleukin-10, News, Pancreatic Cancer, pegilodecakin


March 2nd, 2017

Preliminary Results Suggest That Pamrevlumab is Promising in Pancreatic Cancer

By

Updated results from an ongoing clinical study of pamrevlumab (FG-3019) in combination with standard-of-care chemotherapy in patients with locally advanced pancreatic ductal adenocarcinoma were presented during the ASCO 2017 Gastrointestinal Cancers Symposium in San Francisco and appear to suggest pamrevulmab may improve outcomes compared to chemotherapy alone. About Pancreatic Ductal Adenocarcinoma and Connective Tissue Growth […]

View full entry

Tags: connective tissue growth factor, News, Pamrevlumab. FG-3019, Pancreatic Cancer


February 17th, 2017

Proton beam therapy may improve outcomes for pancreatic cancer

By

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum, pancreatic, or small intestine. This treatment approach is often associated with improved outcomes but the radiation may also cause […]

View full entry

Tags: News, Pancreatic Cancer, radiation


October 4th, 2016

A New Drug That ‘Wakes Up’ Immune System Appears to Fight Pancreatic Cancer

By

A novel drug, IMM-101 has extended the lives of some people with metastatic pancreatic cancer and appears to have minimal side-effects. Doctors describe IMM-101 as “waking up” the immune system to attack cancer. Patients who were given the new immunotherapy drug actually felt better than those who were on standard chemotherapy, said Angus Dalgleish, professor […]

View full entry

Tags: gemcitabine, IMM-101 Gemzar, immunotherapy, News, Pancreatic Cancer


August 17th, 2016

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving

By

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice published August 10 in Nature. The study was led by researchers from NYU Langone Medical Center, the Dana Farber Cancer Institute […]

View full entry

Tags: autophagy, fuel, HCQ, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer, stellate cells, study, tumors


June 6th, 2016

A New Standard of Care of Treatment for Resectable Pancreatic Cancer?

By

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting the European Study Group for Pancreatic Cancer (ESPAC)-4 has presented results that will change the management of pancreatic cancer. Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the […]

View full entry

Tags: 2016, asco, capecitabine, ESPAC-4, European Study Group for Pancreatic Cancer, gemcitabine, gemzar, immunotherapy, mesothelin-directed cells, News, Pancreatic Cancer, Xeloda


May 25th, 2016

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

By

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts. Counsyl’s […]

View full entry

Tags: asco, ASCO16, ASCO2016, BRCAtesting, breast, Breast Cancer, breastcancerawareness, colon, Colon Cancer, DNAtesting, genetic testing, inherited cancer screen


February 11th, 2016

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents

By

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or Xeloda (capecitabine), or who develop certain severe […]

View full entry

Tags: Anal Cancer, Breast Cancer, capecitabine, Colon Cancer, fda, fluorouracil, Gastric Cancer, Gastrointestinal Stromal Tumors, life-threatening, Liver Cancer, News, Pancreatic Cancer


December 1st, 2015

Investigational Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers

By

COLUMBUS, Ohio – New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in testing, was developed and tested in preclinical studies at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and […]

View full entry

Tags: All Cancer Types, AR-42, cachexia, gastrointestinal cancers, HDAC, muscle wasting, News, Pancreatic Cancer, Types of Cancer


November 3rd, 2015

Onivyde Approved for Pancreatic Cancer

By

The United States Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer. The approval is indicated for patients with pancreatic cancer that has spread to distant sites in the body who have received prior treatment with the chemotherapy agent, […]

View full entry

Tags: advanced, fluorouracil, irinotecan liposome injection, leucovorin, News, Onivyde, Pancreatic Cancer, Stage IV Pancreatic Cancer


August 6th, 2015

Protein Circulating in Blood Could Be Key to Early Diagnosis of Pancreatic Cancer

By

Research suggests a promising new way to screen for and detect early pancreatic cancer. Certain proteins that circulate in the blood may help identify patients with this disease, for which there’s currently no reliable screening. These findings were published in the journal Nature. Pancreatic cancer is one of the deadliest forms of cancer. Each year, […]

View full entry

Tags: cancer screening, genomic testing, News, Pancreatic Cancer, pancreatic screening, Screening/Prevention Pancreatic Cancer


June 24th, 2015

“Boosted” Radiation Dose May Make Some Pancreatic Cancers Resectable

By

Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more difficult and sometimes impossible. Researchers at Fox Chase Cancer Center have identified a way to safely […]

View full entry

Tags: neoadjuvant therapy, News, non-metastatic, Pancreatic Cancer, radiation, Stages I-III Pancreatic Cancer


November 26th, 2014

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer

By

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer, based on data from the phase III NAPOLI-1 study that were presented at the 2014 World Congress on Gastrointestinal Cancer in June 2014. MM-398 […]

View full entry

Tags: mm-398, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


October 7th, 2014

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer

By

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage, and treatment of advanced disease remains challenging. The current standard of care consists of […]

View full entry

Tags: News, Pancreatic Cancer, pegph2, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


September 23rd, 2014

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer

By

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage, and treatment of advanced disease remains challenging. Gemzar has been a standard chemotherapy drug […]

View full entry

Tags: gemzar, gilead, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, simtuzuma, Stage IV Pancreatic Cancer